Menu
 
Buscar en la Web Buscar en la Agenda

Agenda

Actividades Académicas
Atrás

XVII INTERNATIONAL SCHOOL OF PHARMACOLOGY ‹TEÓFILO HERNANDO›. FRONTIER THERAPIES IN BRAIN DISEASES: FOCUS ON PURINERGIC SIGNALLING

Información General

Programa

Información General

Procedimiento solicitud onlineProcedimiento solicitud online

BECAS

Relación de BecariosRelación de Becarios

Enlace

Código
63U8
Horas
30
Fecha
23 Jul 2018
27 Jul 2018
Precio
130 € Tarifa C
Tipo
Escuela
Temática
Medicina y Ciencias de la Salud
ECTS
1

Sede donde se gestiona

Santander

Lugar de impartición

Santander - Península de la Magdalena (Rector Ernest Lluch)

Dirección

Tobias Engel
Royal College of Surgeons in Ireland, Dublin, Ireland

Antonio G. García
Instituto Fundación Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Madrid, Spain


Secretaría

Luis Gandía
Instituto Fundación Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Madrid, Spain


COLABORACIÓN


COLABORACIÓN

Descripción de la actividad

The International School of Pharmacology “Teófilo Hernando” of the Universidad Internacional Menéndez Pelayo (UIMP) took this name to honour the memory of Professor Teófilo Hernando who, at the beginning of the XX century, introduced pharmacology as an academic subject and as a science at Spanish University. The School was started in 1996. Since then, 16 editions on different medical themes have been run. This XVII edition is monographically dedicated to frontier therapeutic and biomarker discoveries in chronic diseases focusing on purinergic signalling.  

Classically, the School is organised in 10 morning sessions in which renowned international scientists participate as speakers. In the afternoon sessions, 24 young researchers present short communications followed by ample discussions, on their predoctoral or postdoctoral work. 

This 17th edition focuses on early pathogenic features and therapeutic aspects of chronic diseases in particular brain diseases. The interest in early diagnosis and in finding a therapy that delays disease progression are central stage of this School. 

The enormous burden of brain diseases to society is growing due to population ageing. Thus, we expect that deep analysis of frontier knowledge and live debates, two characteristics of this School, will shed light on pathogenic mechanisms and the therapeutic perspectives to mitigate such burden to patients and their families.

Participantes

DIRECCIÓN

Tobias Engel
Royal College of Surgeons in Ireland, Dublin, Ireland

Antonio G. García
Instituto Fundación Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Madrid, Spain

SECRETARÍA

Luis Gandía
Instituto Fundación Teófilo Hernando de I+D del Medicamento
Universidad Autónoma de Madrid, Madrid, Spain

PARTICIPANTES

Marc Ceusters
Janssen Pharmaceutica, Beerse, Belgium

Francesco di Virgilio
University of Ferrara, Ferrara, Italy

Miguel Díaz Hernández
Universidad Complutense de Madrid

Bruno Frenguelli
University of Warwick, Coventry, UK

Carlos Matute Almau
Universidad del País Vasco, Leioa, Spain

María Teresa Miras Portugal
Universidad Complutense de Madrid, Madrid, Spain

Annette Nicke
Ludwig-Maximilians-Universität München, Germany

Pablo Pelegrín
Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

Programa

Lunes, 23 Julio 2018

10:00
Inauguration by UIMP authorities and School directors

10:30
Opening lecture: Purinergic receptors: impact on brain diseases with specific focus on the ATP-gated P2X7 receptor
María Teresa Miras Portugal

12:15
ATP-gated purine receptors as novel drug targets in epilepsy
Tobias Engel

15:00
Young Researcher Presentations (1) (PurinesDX project PhD students)
Moderación: Luis Gandía

Martes, 24 Julio 2018

10:00
Use of novel mouse models to study P2X7 localization and function
Annette Nicke

12:00
Purinergic signalling in multiple sclerosis
Carlos Matute Almau

15:00
Young Researcher Presentations (2) (PurinesDX project PhD students)
Moderación: Luis Gandía

Miércoles, 25 Julio 2018

10:00
Role of tissue nonspecific alkaline phosphatase in the CNS, relevance in physiological and pathological processes
Miguel Díaz Hernández

12:00
P2X7 receptor as drug target in human sepsis
Pablo Pelegrín

15:00
Young Researcher Presentations (3)
Moderación: Luis Gandía

Jueves, 26 Julio 2018

10:00
ATP and purinergic receptors: new players in the tumor microenvironment
Francesco di Virgilio

12:00
Release, role and replenishment of the purines in the CNS
Bruno Frenguelli

15:00
Round table: The art of publishing in high score journals
Bruno Frenguelli

15:30
Young Researcher Presentations (4)
Moderación: Luis Gandía

Viernes, 27 Julio 2018

10:00
Calcium signaling, neuronal death and a dual neuroprotection strategy linked to P2X7 and NMDA receptors
Antonio G. García

11:30
P2X7R ligands for brain diseases from an industry point of view
Marc Ceusters

12:45
Closing ceremony